Connect with us

Hi, what are you looking for?

Life Sciences

NUROSENE ENTERS INTO AGREEMENT WITH TAYLORED BIOTHERAPEUTICS TO EVALUATE CLINICAL TRIAL RESULTS

Canada NewsWire

Nurosene, via its wholly owned subsidiary NetraMark, will utilize its advanced AI solutions to validate Taylored Biotherapeutics platform technology and help create the optimal clinical trial design for their Phase 3 program.

TORONTO,
June 22, 2022
/CNW/ –
Nurosene Health Inc
. (“Nurosene” or the “Company”) (CSE: MEND) (
Frankfurt
: 8TV) (OTC: MNNDF), a healthtech company focused on delivering innovative AI-based technology solutions for mental performance and wellness, enters into a Master Service Agreement with Taylored Biotherapeutics (“Taylored”), an early-stage biotechnology company focused on developing safe and effective microbial based therapies, or ‘psychobiotics’, to treat mental illness.

As part of the MSA, a fixed fee-based Scope of Work (SOW) has been agreed to, whereby Taylored will utilize Nurosene’s NetraAI technology to evaluate clinical trial results.

“The exciting work that is happening at Taylored Biotherapeutics approaches mental health via the gut microbiome, which generates complex data sets for heterogeneous patient populations. This makes our NetraAI the perfect platform to support their AI pipeline as they advance through their clinical trials. We are looking forward to partnering with the team from Taylored to advance their efforts,” said Dr.
Joseph Geraci, Chief Scientific Officer.

Nurosene, via its wholly owned subsidiary NetraMark, has developed a new paradigm for AI by using new biologically inspired methods to move us from machines that simply learn what we ask them to learn, to machines that teach us about disease and generate novel ways to stratify and treat patients. Taylored Biotherapeutics will be utilizing this Explainable Artificial Intelligence (XAI) to help validate their platform technology and create the optimal clinical trial design for their clinical trial programs.

“NetraMark brings the level of AI sophistication we need to take our platform technology to the next level,” says
Valarie Taylor, CEO of Taylored Biotherapeutics.

Taylored Biotherapeutics has developed a breakthrough technology platform to engineer live bacterial strains to treat complex mental health conditions. The findings from this project will be essential to stratify the response to fecal microbiota transplantation (FMT) and evaluate the efficacy of this treatment in a bipolar disorder depression patient cohort.

The MSA was signed on
June 20, 2022
and will be effective from this date (“Effective Date”) and shall continue thereafter until terminated.

About Taylored Biotherapeutics

Taylored Biotherapeutics is a bio-entrepreneurial company focused on developing safe and effective microbial based therapies, or ‘psychobiotics’, to treat mental illness. We take a human first, patient informed approach to create a precision medicine product. Our only focus is on improving the treatment options available for those with mental illness. For more information go to:
https://www.tayloredbio.com/
.

About Nurosene

Nurosene is an AI healthtech company focused on addressing both acute and non-acute brain-centric conditions. We have developed an ecosystem of innovative products that directly support brain-related conditions. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.

For more information, visit
www.nurosene.com
.

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which is based upon Nurosene’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene’s Final Long Form Prospectus dated
May 20, 2021
and Management’s Discussion and Analysis for the year ended
September 30, 2021
(“MD&A”), and filed with the applicable Canadian securities regulatory authorities on SEDAR at
www.sedar.com
. The risk factors and other factors noted in Nurosene’s Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

Cision
View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/June2022/22/c7000.html

You May Also Like

Blog

An investor’s best friend is the candlestick chart, which you can use to identify trends in stocks, commodities, and currencies. The most reliable patterns...

Technology

The blog post breaks down what are candlestick patterns, how to read easy to see patterns, how candlesticks are formed, how to read charts,...

Diversified Industries

This blog breaks down the essential candlestick patterns that will help traders with investing. Also, investors are encouraged to look into the body, wick,...

Diversified Industries

In this blog we explore the top 6 unknown and cheap stocks for millennials to invest in. This list includes: Zynga (NASDAQ:ZNGA), Franks International...

Investor Scene

InvestorScene.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, in-depth broadcasts on Stock News, Market Analysis and Company Interviews.

InvestorScene.com also provides financial news PR marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.



Copyright © 2022 www.investorscene.com - a GloBull Media, LLC Brand